Just a matter of time for SQI's multiplex capabilities...... Participants with antibody levels in the top 10% had a 10 times lower risk of symptomatic COVID-19 compared with participants who had undetectable or negative antibody values. This was the case no matter which antibody biomarker the researchers focused on.
MNT spoke with Dr. Peter Gilbert, a professor in the Vaccine and Infectious Disease Division of Fred Hutchinson Cancer Research Center, in Seattle, and the corresponding author of the study.
Summarizing the findings, Dr. Gilbert explained, “Four separate tests used to measure antibody levels in the blood showed that the higher a vaccine recipient’s antibody response, the less likely [they were] to experience symptomatic COVID-19.”
“The same measurements also indicated that higher antibody responses correlated with higher estimated vaccine efficacy against symptomatic COVID-19.”
“The findings are based on data from the phase 3 COVE trial, which enrolled more than 30,000 adult volunteers and established 94.1% estimated vaccine efficacy against COVID-19 for the mRNA-1273 vaccine,” Dr. Gilbert added.
He also noted that the findings may help accelerate the approval process for future vaccines.
“Correlates of protection are surrogate markers of efficacy that can be used to reliably predict whether a vaccine will be protective, which can accelerate regulatory authorization and approval of vaccine candidates.”
Medical News Today.COVID-19 vaccines: Antibody levels might help speed up ....In a new study, scientists have found that antibody levels can help indicate the effectiveness of the Moderna COVID-19 vaccine..1 hour ago